Sunshine Biopharma Inc (SBFM)

[BooDog]

SUNSHINE BIOPHARMA INC (quick info)
ANTICANCER RESEARCH 32: 4423-4432 (2012)
Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective against Multidrug Resistant Human Cancer Cells

Excerpt…
In the search for novel etoposide analogs with improved efficacy and pharmacokinetic properties, which can overcome multidrug resistance of human cancer cells, we designed and synthesized Adva-27a, a non-ester, nitrogen-containing glycoside analog of etoposide (Figure 1C). This study describes the evaluation of Adva-27a using a battery of biochemical, cell biological, and pharmacological analyses. Compared to etoposide, Adva-27a was found to be substantially more potent against two multidrug-resistant human cancer cell lines, and has a better metabolic stability and pharmacokinetic properties than etoposide. Taken together, these results suggest that further development of Adva-27a is warranted as a novel topoisomerase II inhibitor for use in human cancer therapy with multidrug-resistant tumors.

http://sunshinebiopharma.com/wp-content/uploads/2013/05/Adva27a_Published_Manuscript.pdf

Patents
Sunshine Biopharma holds the exclusive rights to Adva-27a in the United States. We received this license from Advanomics Corporation which owns the international patent applications filed on April 27, 2007 (PCT/FR2007/000697). These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation. On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and other compositions.
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,236,935.PN.&OS=PN/8,236,935&RS=PN/8,236,935

• Adva-27a is effective at killing different types of multidrug resistant cancer cells, including:
•
• Breast Cancer (MCF-7/MDR cell line)
• Small Cell Lung Cancer (H69AR cell line)
• Uterine Sarcoma (MES-SA/Dx5 cell line)
• Pancreatic Cancer (Panc-1 cell line)
• Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
• Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.
• Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
• Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 1.44 micromolar.
• Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.
• Adva-27a does not inhibit tubulin assembly.

Dr. Steve Slilaty
Profile
Dr. Steve N. Slilaty, age 57, was appointed as our CEO, President and Chairman of our Board of Directors on October 15, 2009. In addition, since February 2002, Dr. Slilaty has been President and Chief Scientific Officer of Advanomics Corporation, Montreal, Canada, a privately held company engaged in the research, development and commercialization of drugs for the treatment of various forms of cancer. Advanomics Corporation is the third in a line of biotechnology companies that Dr. Slilaty founded and managed through their early and mid stages of development. The first, Quantum Biotechnologies Inc. later known as Qbiogene Inc., was founded in 1991 and grew to over $60 million in annual sales. Today, Qbiogene is a member of a family of companies owned by MP Biomedicals, one of the largest international suppliers of biotechnology reagents with a catalogue containing over 55,000 products. The second company which Dr. Slilaty founded, Genomics One Corporation, now known as Alert B&C Corporation, conducted an initial public offering (IPO) of its capital stock in 1999 and, on the basis of its ownership of Dr. Slilaty's patented TrueBlue Technology, Genomics One became one of the handful of participants in the Human Genome Project. Formerly a research team leader of the Biotechnology Research Institute, a division of the National Research Council of Canada, Dr. Slilaty also served as a consultant in a management and advisory capacity for a major Canadian biotechnology company between 1995 and 1997 during which time the company completed one of the largest biotechnology IPO‘s in Canada raising over $34 million. Dr. Slilaty received his Ph.D degree from the University of Arizona in 1983 and a Bachelor of Science degree from Cornell University in 1976. In addition, Dr. Slilaty holds a position as Adjunct Professor at Universit-é du Qu-ébec in the Department of Microbiology and Biotechnology.

Headquarters
Sunshine Biopharma Inc.
469 Jean-Talon West
3rd Floor
Montreal, Quebec H3N 1R4
Canada
Phone: [phone]
Fax: [phone]
Direct: 514-814-0464
Email: [e-mail]
3rd floor office.
https://cbks0.google.com/cbk?output=thumbnail&cb_client=maps_sv&thumb=2&thumbfov=69&ll=45.528816,-73.623150&yaw=302.4&thumbpegman=1&w=300&h=118



McGill University’s Jewish General Hospital
http://www.mcgill.ca/palliativecare/clinical-care/jewish-general-hospital

SEC filings...
http://www.sec.gov/cgi-bin/browse-edgar?company=sunshine+biopharma&match=contains&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany


http://sunshinebiopharma.com/investor/sec-filings/

http://finance.yahoo.com/q?s=sbfm

The number of shares of the registrant’s only class of common stock issued and outstanding as of August 12, 2014, was 68,270,961 shares.
The number of shares of the registrant’s only class of common stock issued and outstanding as of August 5, 2013 was 56,439,061 shares.
Authorized 200,000,000 Shares.


SUNSHINE BIOPHARMA’S WHOLLY OWNED CANADIAN SUBSIDIARY COMPLETES THE SOP’S REQUIRED BY HEALTH CANADA TO SECURE DRUG ESTABLISHMENT LICENSE
Montreal, Quebec, Canada -- (MARKETWIRE) -- Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has completed the drafting of all of the Standard Operating Procedures (SOP’s) required by Health Canada for the procurement of a Drug Establishment License (DEL). The completed SOP’s comprise 18 binders and over 2,000 pages of documentation. It is necessary for Sunshine to have the DEL in place in order to become a fully integrated pharmaceutical company with proprietary (Adva-27a) and generic pharmaceutical products offering.
“In addition to the generic pharmaceutical business unit we are putting into place, we are moving full speed ahead with the development of our flagship proprietary anticancer drug, Adva-27a,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. “Not unlike other fully integrated pharmaceutical companies, Sunshine plans to fund its proprietary drug development program through the sale of generic pharmaceuticals around the world. This is an important strategic positioning of the Company in order to become less dependent, if at all, on capital markets for the financing of our operations.”

SUNSHINE BIOPHARMA NEGOTIATING WITH CRO’s TO INITIATE MASTER DRUG FILE FOR Adva-27a ANTICANCER COMPOUND Montreal, Quebec, Canada -- (MARKETWIRE) -- Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is currently negotiating with several Contract Research Organizations (CRO’s) with the intent to engage one of them for the purposes of initiating, compiling and managing a regulatory master drug file for Adva-27a, the Company’s flagship anticancer compound. A master drug file contains all of the information that regulatory agencies require as part of the drug development and approval process. Such information includes preclinical data, GMP manufacturing process, large animal studies and human trials. “Engaging a CRO is the next step in our Adva-27a drug development program,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. “We are delighted to have arrived at this advanced stage in the development of our Adva-27a. The CRO will compile the testing results conducted to date, follow and document the GMP manufacturing process, manage the large animal studies and file with the appropriate regulatory agencies for go-ahead with Phase I human trials.”

SUNSHINE BIOPHARMA’S WHOLLY OWNED CANADIAN SUBSIDIARY ENGAGES HEALTH CANADA SPECIALIZED CONSULTANTS TO SECURES PHARMACEUTICAL ESTABLISHMENT LICENSE
Montreal, Quebec, Canada -- (MARKETWIRE) -- Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has engaged consultants specialized in Health Canada procedures and requirements to prepare the necessary documentations and applications for the procurement of a Pharmaceutical Establishment License. Such licensing must be in place before the Company is able to sign manufacturing and distribution contracts and accept purchase orders for the sale of pharmaceutical products. “We are anxious to have our Pharmaceutical Establishment License in place in order to be able to capitalize on attendant opportunities with a potential to generate revenues in the near term,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. “Profits from such operations will be used to fund our proprietary drug development program including Adva-27a, our flagship oncology drug candidate currently being developed for the treatment of Pancreatic Cancer and Multidrug Resistant Breast Cancer. This will make us less dependent on capital markets for financing of our drug development operations.”


====================================

FYI
There has been a lot of non sense posted on this board. For easier reading those members can be placed on ignore.